Mutagenesis and oncogenesis by chromosomal insertion of gene transfer vectors
- PMID: 16544975
- DOI: 10.1089/hum.2006.17.253
Mutagenesis and oncogenesis by chromosomal insertion of gene transfer vectors
Abstract
Increasing evidence reveals that random insertion of gene transfer vectors into the genome of repopulating hematopoietic cells may alter their fate in vivo. Although most insertional mutations are expected to have few if any consequences for cellular survival, clonal dominance caused by retroviral vector insertions in (or in the vicinity of) proto-oncogenes or other signaling genes has been described for both normal and malignant hematopoiesis. Important insights into these side effects were initially obtained in murine models. Results from ongoing clinical studies have revealed that similar adverse events may also occur in human gene therapy. However, it remains unknown to what extent the outcome of insertional mutagenesis induced by gene vectors is related to (1) the architecture and type of vector used, (2) intrinsic properties of the target cell, and (3) extrinsic and potentially disease-specific factors influencing clonal competition in vivo. This review discusses reports addressing these questions, underlining the need for models that demonstrate and quantify the functional consequences of insertional mutagenesis. Improving vector design appears to be the most straightforward approach to increase safety, provided all relevant cofactors are considered.
Similar articles
-
Monitoring for potential adverse effects of prenatal gene therapy: genotoxicity analysis in vitro and on small animal models ex vivo and in vivo.Methods Mol Biol. 2012;891:341-70. doi: 10.1007/978-1-61779-873-3_16. Methods Mol Biol. 2012. PMID: 22648780
-
Insertion of retroviral vectors in NOD/SCID repopulating human peripheral blood progenitor cells occurs preferentially in the vicinity of transcription start regions and in introns.Mol Ther. 2004 Nov;10(5):874-81. doi: 10.1016/j.ymthe.2004.08.001. Mol Ther. 2004. PMID: 15509505
-
Insertional mutagenesis in gene therapy and stem cell biology.Curr Opin Hematol. 2007 Jul;14(4):337-42. doi: 10.1097/MOH.0b013e3281900f01. Curr Opin Hematol. 2007. PMID: 17534158 Review.
-
Cell-intrinsic and vector-related properties cooperate to determine the incidence and consequences of insertional mutagenesis.Mol Ther. 2009 Sep;17(9):1537-47. doi: 10.1038/mt.2009.134. Epub 2009 Jun 16. Mol Ther. 2009. PMID: 19532134 Free PMC article.
-
Mechanisms of retroviral integration and mutagenesis.Hum Gene Ther. 2013 Feb;24(2):119-31. doi: 10.1089/hum.2012.203. Hum Gene Ther. 2013. PMID: 23330935 Review.
Cited by
-
Drug product attributes predict clinical efficacy in betibeglogene autotemcel gene therapy for β-thalassemia.Mol Ther Methods Clin Dev. 2023 Nov 10;31:101155. doi: 10.1016/j.omtm.2023.101155. eCollection 2023 Dec 14. Mol Ther Methods Clin Dev. 2023. PMID: 38074412 Free PMC article.
-
Retroviral gene therapy in Germany with a view on previous experience and future perspectives.Gene Ther. 2021 Sep;28(9):494-512. doi: 10.1038/s41434-021-00237-x. Epub 2021 Mar 22. Gene Ther. 2021. PMID: 33753908 Free PMC article. Review.
-
Targeted plasmid integration into the human genome by an engineered zinc-finger recombinase.Nucleic Acids Res. 2011 Sep 1;39(17):7868-78. doi: 10.1093/nar/gkr421. Epub 2011 Jun 7. Nucleic Acids Res. 2011. PMID: 21653554 Free PMC article.
-
Calcium Phosphate Nanoparticles-Based Systems for RNAi Delivery: Applications in Bone Tissue Regeneration.Nanomaterials (Basel). 2020 Jan 14;10(1):146. doi: 10.3390/nano10010146. Nanomaterials (Basel). 2020. PMID: 31947548 Free PMC article. Review.
-
Lentiviral vector-mediated RNA silencing in the central nervous system.Hum Gene Ther Methods. 2014 Feb;25(1):14-32. doi: 10.1089/hgtb.2013.016. Epub 2013 Nov 1. Hum Gene Ther Methods. 2014. PMID: 24090197 Free PMC article. Review.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
